Inhibition of MAP4K4 through RNAI

US9074211B2 · kind B2 · utility

Assignee

• RXi Pharmaceuticals Corporation · US

Inventors

• Tod M. Woolf · Sudbury, US
• Joanne Kamens · Newton, US
• Anastasia Khvorova · Boulder, US
• William Salomon · Worcester, US

Key dates

• Filing date: Nov 19, 2009
• Grant date: Jul 7, 2015
• Expiry date: Jun 6, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.